Compare AbCellera Biologics Inc (ABCL) vs Lucid Group Inc (LCID) Price & Performance

AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.

The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.

Lucid Group (LCID) trades at $5.995, down 1.4% on the day, with a bullish technical signal from moving averages but neutral oscillators. The company reported Q2 2026 deliveries of 3,093 vehicles, missing expectations, alongside a leadership overhaul. Financially, LCID shows severe losses with a net income margin of -239.81% in 2025 and negative cash flow from operations of -$2.93B, though revenue grew to $1.35B.

The outlook remains challenging due to persistent losses and high cash burn, but the consensus price target of $11.75 suggests potential upside if execution improves. Key risks include ongoing class-action lawsuits, competitive pressures in the EV market, and reliance on Saudi funding. Investors should weigh the high-risk profile against long-term growth prospects in electric vehicles.